Celgene pharmaceutical company has provided a detailed look at its progress in fulfilling its corporate responsibility in 2016. The report, “Patients First,” highlights the company’s policies and achievements, including publishing principles for the pricing of innovative medicines, using renewable energy and expanding its engagements with stakeholders around the world.

Here is the letter from Executive Vice President Richard Bagger:

Rich Bagger

Executive Vice President

Corporate Affairs and Market Access

Celgene Corporation

86 Morris Avenue

Summit, NJ 07901


It is my great pleasure to share with you Celgene’s 2016 Corporate Responsibility report: Patients First. This publication is Celgene’s fifth annual report which details the company’s business practices as we responsibly fulfill our commitments to patients, employees, communities and the environment as well as to conduct our business with integrity.

As a deeply science based biopharmaceutical company, we create value for all stakeholders when we develop medicines that improve and extend the lives of patients today, while investing in finding cures for patients in the future. Over the next two years, we expect pivotal data from approximately 20 Phase III programs. These programs, alongside our mid- and early-stage pipeline, create the potential for many innovative new therapies in the years to come. With this rapidly growing portfolio of novel treatments, we are serving an ever increasing number of patients worldwide with new products and additional indications.

This is what we do to pursue our vision, and we are also mindful of how we work and expand our operations responsibly, consistent with our core values. In doing so, we are fulfilling our purpose – to change the course of human health through bold pursuits in science, and a promise to always put Patients First.

This report provides a detailed look at the progress Celgene has made during the reporting period across key areas of engagement. In 2016, Celgene took the initiative to publish our principles for the pricing of innovative medicines. To build on sustainability progress made over the last several years, Celgene also established our first prospective, quantitative environmental targets for carbon emissions, water consumption, solid waste generation and renewable energy purchases for the year We’ve also expanded our engagements with stakeholders around the world as we continue to request specific feedback and dialogue.

To read the 2016 Celgene Corporate Responsibility report and to learn more about Celgene, please visit: www.celgene.com/responsibility.

As you read, I encourage you to let us know your thoughts and to become a part of the Celgene Responsibility dialogue. We welcome your feedback and engagement so please reach out to me directly or Zeba Khan, VP, Corporate Responsibility at responsibility@celgene.com.